| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BeyondSpring, Inc.$1.28
+0.01 (+0.79%)
C 43Pipeline Score Undervalued Pharma · Clinical
Market Cap
64.56 M
EPS
-0.19
P/E Ratio
-
Value Trade
22.53 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
1.08 M
Operating CF
-3.28 M
Total Assets
18.41 M
Total Liabilities
48.76 M
Equity
-34.49 M
D/E Ratio
12,345
9.79 %
Week
-7.65 %
1 Month
20.77 %
3 Month
-11.8 %
6 Month
-84.71 %
5 Year
-92.15 %
All Time
Cash Data
Cash Position
7.86 M
Monthly Burn
1.09 M
Runway
5.2 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
43.90 K
52 Week Range
1.18 - 3.44
% held by Insiders
24.14 %
% held by Institutions
5.31 %
Enterprise Value
61.07 M
Total Shares
41.13 M
Short %
7.11 %
Float Shares
29.70 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BeyondSpring, Inc.
513Total events
1Upcoming
137Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 1
TBD
T2End Of Phase 2 Meeting
Subscribe to view catalyst details
Event history 2
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
TBD
◆Oral PresentationPlinabulinFiledPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-31 | ST-01156 | IND Submission | IND | — | – | – | – |
2026-03-31 | ST-01156 | IND Submission | IND | — | – | – | – |
2026-03-31 | ST-01156 | IND Submission | IND | — | – | – | – |
Drug Pipeline Intelligence
C43
Pipeline Score $204M
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored3.2x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 912)
Percentile RankBeyondSpring, Inc. carries a moderate pipeline score (43/100), with $5.3B risk-adjusted pipeline value, led by Plinabulin in Non-Small Cell Lung Cancer (Phase 3), across $88B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plinabulin Small molecule | Chemotherapy-induced Neutropenia | Phase 3 | NCT04345900 | 90% | $4.4B | COMPLETED | 275 | - | - | Apr 20, 2018 | - | May 16, 2024 |
BYSI Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
pembrolizumab plus Plinabulin and docetaxel BreakthroughPriority | metastatic NSCLC | Phase 2 | 2026-06-02 | Median PFS: 7.0 months; Median Do R: 9.3 months; DCR: 79.5%; 12 Month OS Rate: 78.1%; 24 Month OS Rate: 58.0%; Confirmed ORR: 18.2% Read More | BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 Read More | |
pembrolizumab plus Plinabulin and docetaxel BreakthroughPriority | metastatic NSCLC | Phase 2 | 2026-06-02 | Median PFS: 7.0 months; Median Do R: 9.3 months; DCR: 79.5%; 12 Month OS Rate: 78.1%; 24 Month OS Rate: 58.0%; Confirmed ORR: 18.2% Read More | BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 Read More | |
pembrolizumab plus Plinabulin and docetaxel BreakthroughPriority | metastatic NSCLC | Phase 2 | 2026-06-02 | Median PFS: 7.0 months; Median Do R: 9.3 months; DCR: 79.5%; 12 Month OS Rate: 78.1%; 24 Month OS Rate: 58.0%; Confirmed ORR: 18.2% Read More | BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BYSI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BYSI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
BYSI Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Real-Time BYSI Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
BYSI Option Volume & Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BYSIBeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
BeyondSpring, a clinical-stage biopharmaceutical company, has announced a leadership transition effective July 1, 2026, aimed at executing its confirmatory DUBLIN-4 program for Plinabulin. Dr. Min Qiu has been appointed as CEO with a mandate to drive this pivotal study alongside a strengthened Board led by Dr. Lan Huang, who remains Chairman. The new leadership structure is designed to ensure focused execution and strategic governance, supporting BeyondSpring's goal of establishing Plinabulin as a new standard of care for a significant patient population. The company also emphasizes a solid intellectual property portfolio protecting its assets through 2041.
Read more →BYSIBeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
BeyondSpring Inc. presented updated results from its Phase 2 study of pembrolizumab combined with Plinabulin and docetaxel for metastatic NSCLC patients who progressed after prior immune checkpoint inhibitor therapy. The study demonstrated a median progression-free survival of 7.0 months and a 12-month overall survival rate of 78.1%. The treatment showed good tolerability and a high disease control rate of 79.5%.
Read more →BYSIBeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
BeyondSpring Inc. announced a poster presentation for Study 303 at the 2026 ASCO Annual Meeting. This Phase 2 study evaluates the combination of plinabulin, docetaxel, and pembrolizumab in patients with metastatic NSCLC who have progressed after prior treatments. The presentation is scheduled for May 31, 2026, in Chicago.
Read more →BYSIBeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported its financial results for Q1 2026, highlighting advancements in its cancer treatment pipeline, particularly with Plinabulin, which shows promise as a backbone agent in antibody-drug conjugate therapies. The company also announced the advancement of ST-01156, a molecular glue degrader, into clinical development. Despite these advancements, the company faced a net loss of $2.4 million for the quarter.
Read more →BYSI▼ -6.3%on this news
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
BeyondSpring Inc. (NASDAQ: BYSI) presented new preclinical data at the AACR 2026 meeting showing that Plinabulin can significantly improve the efficacy and safety profiles of antibody-drug conjugates (ADCs). The results indicate that Plinabulin enhances complete tumor response rates while simultaneously reducing neutropenia, a common side effect that limits ADC treatment. This positions Plinabulin as a promising candidate for combination therapies, potentially transforming the landscape of cancer treatment. The findings support ongoing and future clinical trials that aim to validate these benefits across various cancer indications.
Read more →BYSIBeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
BeyondSpring Inc. announced a poster presentation at the 2026 AACR Annual Meeting, scheduled for April 21, 2026. The presentation will focus on the efficacy of Plinabulin in enhancing the effects of topoisomerase inhibitor-based antibody-drug conjugates. The event will take place in San Diego, California, highlighting advancements in cancer treatment.
Read more →BYSIBeyondSpring Files 2025 Annual Report on Form 10-K
BeyondSpring Inc. has filed its annual report on Form 10-K for the fiscal year ending December 31, 2025. This report includes the company's audited consolidated financial statements and is accessible on the SEC's website. The company continues to focus on developing innovative therapies for cancer treatment, particularly its lead asset, Plinabulin.
Read more →BYSIBeyondSpring Reports 2025 Year-End Financial Results
BeyondSpring reported positive financial results for 2025, highlighting significant progress in its lead program, Plinabulin, which demonstrated a survival benefit in a Phase 3 study for NSCLC. The company plans to advance a confirmatory Phase 3 trial, DUBLIN-4, and has strengthened its financial position with new funding. SEED Therapeutics also made strides with its first clinical program.
Read more →BYSIBeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
BeyondSpring Inc. will participate in the Immuno-Oncology 360° Conference 2026, scheduled for February 10-12 in Boston, MA. Dr. Lan Huang, the company's CEO, will present on Plinabulin, emphasizing its role in overcoming PD-1/L1 resistance. The presentation aims to showcase Plinabulin's unique mechanism and clinical development strategy.
Read more →BYSIBeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
BeyondSpring Inc. announced promising results from the Asian subset of its Phase 3 DUBLIN-3 trial, showing that Plinabulin combined with docetaxel significantly improves overall survival in patients with EGFR wild-type non-small cell lung cancer. This combination achieved a median overall survival of 10.8 months compared to 8.8 months for docetaxel alone, particularly benefiting non-squamous patients. The trial's findings highlight Plinabulin's ability to enhance chemotherapy tolerability and reduce the incidence of severe side effects. These results support the potential of Plinabulin as a new treatment standard for NSCLC.
Read more →BYSI▲ +7.9%on this newsshared move
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
BeyondSpring announced positive post-hoc analyses from the DUBLIN-3 Phase 3 study, indicating that Plinabulin combined with docetaxel offers significant survival benefits for patients with EGFR wild-type non-squamous NSCLC who have progressed after anti-PD-(L)1 therapy. The findings were presented at the 2025 NACLC and highlight the potential of Plinabulin to address unmet medical needs in this patient population. A global Phase 3 DUBLIN-4 trial is planned to further support these findings.
Read more →BYSIBeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported its Q3 2025 financial results, highlighting the progress of its lead asset, Plinabulin, which has shown a favorable safety profile in over 700 patients. The company also announced IND clearance for its RBM39 molecular-glue degrader. The results from the Phase 3 DUBLIN-3 trial indicate potential for Plinabulin to enhance cancer treatment standards. However, the company faces risks related to financing and regulatory approvals.
Read more →BYSIBeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
BeyondSpring Inc. reported its Q2 2025 financial results, highlighting significant clinical advancements and a strategic leadership appointment. The company emphasized the potential of Plinabulin, a first-in-class cancer treatment, in improving outcomes for patients with non-small cell lung cancer. Additionally, SEED Therapeutics, in which BeyondSpring holds a stake, received FDA clearance for its innovative cancer-targeting agent.
Read more →BYSIBeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
BeyondSpring Inc. announced the publication of a human clinical study in Med, demonstrating that Plinabulin, in combination with radiation and checkpoint inhibitors, can induce dendritic cell maturation and tumor responses in patients who previously failed ICI therapy. The study highlights the potential of Plinabulin in treating various cancer types and identifies a biomarker for patient selection. The results suggest a promising avenue for overcoming ICI resistance.
Read more →BYSIBeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BeyondSpring presented interim Phase 2 data at the 2025 ASCO Annual Meeting, showing promising results for Plinabulin combined with pembrolizumab and docetaxel in treating metastatic NSCLC after progression on first-line therapies. The study involved 47 patients, highlighting the potential of Plinabulin to overcome resistance to checkpoint inhibitors. The findings suggest improved survival rates and reduced severe neutropenia compared to existing treatments.
Read more →BYSI▼ -5.7%on this news
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
BeyondSpring Inc. announced a poster presentation for the 303 Study at the 2025 ASCO Annual Meeting. This study evaluates the efficacy of Plinabulin combined with docetaxel and pembrolizumab for patients with metastatic NSCLC who have progressed after prior treatments. The presentation will occur from May 30 to June 3 in Chicago, IL.
Read more →BYSIBeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
BeyondSpring Inc. has announced its financial results for Q1 2025, highlighting the early efficacy of Plinabulin in treating metastatic NSCLC and Hodgkin lymphoma. The company is also progressing towards an IND filing for its RBM39 degrader aimed at Ewing sarcoma. However, BeyondSpring reported a loss from continuing operations that increased compared to the previous year, attributed to rising research and administrative expenses. Overall, while there are promising developments in clinical efficacy, the financial outlook remains challenging.
Read more →BYSIBeyondSpring Files 2024 Annual Report on Form 10-K
BeyondSpring Inc. has filed its annual report on Form 10-K for the fiscal year ending December 31, 2024. The report, which includes audited financial statements, is available on the SEC's website and the company's site. BeyondSpring is focused on developing innovative cancer therapies, particularly its lead asset, Plinabulin, which is in late-stage clinical development.
Read more →BYSIBeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
BeyondSpring Inc. reported its 2024 financial results, highlighting significant clinical progress for its lead drug Plinabulin, which demonstrated survival benefits in NSCLC patients. The company also noted strategic advancements through partnerships with Eisai and Eli Lilly, as well as developments in its SEED Therapeutics subsidiary. The outlook for 2025 appears positive, with plans to navigate regulatory pathways effectively.
Read more →BYSI▲ +6%on this news
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
BeyondSpring Inc. announced the sale of a portion of its equity interest in SEED Therapeutics for approximately $35.4 million. This funding will support the late-stage clinical trials of its lead asset, Plinabulin, a first-in-class anti-cancer agent. BeyondSpring retains about 14.4% ownership in SEED, ensuring continued involvement in its innovative drug discovery efforts.
Read more →BYSIBeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
BeyondSpring Inc. presented updated efficacy results from its phase 2 IIT study on a triple combination of pembrolizumab, plinabulin, and docetaxel for metastatic NSCLC. The study, involving 30 patients, reported a confirmed overall response rate of 21.1% and a median progression-free survival of 8.6 months. The combination has shown a high disease control rate of 89.3%, despite an incidence of grade 3 or higher treatment-related adverse events in nearly half of the patients. The ongoing study aims to further assess this innovative therapy's potential in a population with high unmet medical needs.
Read more →BYSI▼ -5.2%on this news
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
BeyondSpring Inc. presented interim results from the 303 Study at ESMO Congress 2024, evaluating the efficacy and safety of a combination of pembrolizumab, plinabulin, and docetaxel in metastatic NSCLC patients who have progressed on first-line immune checkpoint inhibitors. The interim analysis included 19 patients, showing a confirmed overall response rate of 21.1% and a median progression-free survival of 8.63 months, with a disease control rate of 89.5%. While the regimen was well tolerated, noteworthy adverse effects were observed, with over half of the participants experiencing grade 3 or higher treatment-related issues.
Read more →BYSI▼ -5.2%on this news
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
BeyondSpring presented final data from its DUBLIN-3 Phase 3 study at the ESMO Congress 2024, showcasing the effectiveness of the plinabulin/docetaxel combination for patients with 2L/3L EGFR wild-type NSCLC. The results indicated significant improvements in overall survival and quality of life, along with a notable reduction in severe neutropenia compared to docetaxel alone. As the standard of care often results in high rates of severe neutropenia, this combination represents a potentially beneficial new option for patients lacking targetable alterations. The study underscores the therapeutic promise of plinabulin in enhancing the efficacy of existing treatments.
Read more →BYSIBeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
BeyondSpring Inc. announced positive final phase 3 data for its lead anti-cancer asset, Plinabulin, at the ISLAC 2024 conference. The data revealed significant improvements in overall survival and progression-free survival when Plinabulin was combined with docetaxel for patients with EGFR wild-type non-small cell lung cancer (NSCLC) after platinum-based therapy failure. The DUBLIN-3 study highlighted a favorable benefit/risk ratio and a notable reduction in severe neutropenia occurrences. These promising results were also published in the Lancet Respiratory Medicine, indicating a potential new treatment option for patients with high unmet medical needs.
Read more →BYSI▼ -5.4%on this news
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
BeyondSpring Inc. has announced it will showcase its lead anti-cancer asset, Plinabulin, with an oral presentation at the 2024 World Conference on Lung Cancer and two poster presentations at the ESMO Congress 2024. The oral presentation will focus on the final efficacy data from the Dublin-3 phase 3 study comparing Plinabulin and docetaxel against docetaxel alone for treating non-small cell lung cancer. The presentations are to take place in September 2024, highlighting the potential impact of Plinabulin in late-stage clinical development for lung cancer therapies.
Read more →BYSISEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications SEED Concurrently Enters in
SEED Therapeutics has entered into a strategic research collaboration with Eisai Co., Ltd. to discover and develop novel molecular glue degraders targeting neurodegeneration and oncology. Concurrently, SEED is securing a Series A-3 financing led by Eisai, starting with $24 million, intended to accelerate its clinical development. The collaboration builds on previous partnerships aimed at treating complex diseases with limited treatment options, potentially advancing the field of targeted protein degradation. SEED's executives express optimism about the collaboration's ability to deliver innovations for patients with high unmet medical needs.
Read more →BYSIBeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Inc. held its virtual R&D Day on May 15, 2024, to discuss the development of its lead asset Plinabulin and updates from SEED Therapeutics. Key Opinion Leaders presented insights on Plinabulin's potential in combination therapies for patients who have not responded to PD-1/PD-L1 inhibitors. The company highlighted positive phase 3 trial results demonstrating improved survival rates. SEED is advancing its TPD platform for drug discovery, with plans to file an IND for a new cancer treatment by early 2025.
Read more →BYSIBeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Inc. has announced it will host a virtual Research and Development Day on May 15, 2024, to discuss the future strategy for its cancer therapy Plinabulin and updates from its subsidiary SEED Therapeutics. Esteemed experts from cancer research institutions will highlight Plinabulin's potential in addressing unmet medical needs after immune-checkpoint-inhibitor therapy. The event will also include discussions on the company’s broader technology and pipeline developments. This forum aims to inform investors and stakeholders about ongoing advancements in cancer treatments.
Read more →BYSIBeyondSpring Files 2023 Annual Report on Form 20-F
BeyondSpring Inc. has filed its 2023 annual report on Form 20-F with the SEC. The report contains audited financial statements and is available to shareholders upon request. The company is advancing its lead asset, Plinabulin, for cancer therapy and has preclinical assets in immuno-oncology. However, there are notable risks regarding the company's future operations and funding.
Read more →BYSIBeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Inc. provided a business update and released its financial results for 2023, revealing advancements in clinical programs, particularly with its lead asset, Plinabulin. The company has initiated several Phase 2 investigator-initiated trials and has partnered with major institutions for its studies. Additionally, its subsidiary, SEED Therapeutics, has made notable strides in drug discovery, especially in collaboration with Eli Lilly. Despite ongoing financial losses, the company is strategically positioning itself in the competitive biopharma landscape.
Read more →BYSI▲ +11.2%on this news
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring Inc. has announced the dosing of the first patient in a Phase 2 investigator-initiated trial combining Pembrolizumab, Plinabulin, and Etoposide/Platinum for first-line treatment of Extensive-Stage Small-Cell Lung Cancer. This trial aims to evaluate the therapy's efficacy and safety, responding to a significant unmet medical need due to current treatments' limited effectiveness. Lead investigator Dr. Xiaorong Dong expressed optimism regarding the potential for Plinabulin to enhance patient responses and improve progression-free survival rates. The study is being conducted at Wuhan Union Hospital in China.
Read more →BYSI▲ +9.2%on this news· ran to +22% by day 3
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
BeyondSpring Inc. announced that it has regained compliance with Nasdaq's minimum bid price and periodic filing requirements on February 20, 2024. The company demonstrated a closing bid price of $1.00 or greater for ten consecutive business days, which resolved the prior deficiency matter. Additionally, the company has fulfilled its periodic filing obligations, indicating improved operational compliance. BeyondSpring continues to focus on innovative therapies aimed at addressing significant unmet medical needs in oncology.
Read more →BYSIBeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
BeyondSpring Inc. has received a delinquency notice from Nasdaq regarding its late filing of Form 6-K, which was due for the period ended June 30, 2023. The company has 60 days to submit a plan to regain compliance, and successful acceptance of this plan may grant them up to 180 days to rectify the issue. Despite this notice, there is no immediate effect on the company's stock listing or trading activities. The management is actively working to complete the needed filings.
Read more →BYSIBeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
BeyondSpring Inc. received a notification from Nasdaq indicating that it does not meet the minimum bid price requirement of $1.00 per share, with shares trading below this threshold for 31 consecutive days. The company has 180 days to comply, during which time its shares will continue to trade on Nasdaq. The notification does not trigger an immediate delisting, and BeyondSpring is exploring options to achieve compliance within the specified timeframe.
Read more →BYSIBeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
BeyondSpring Inc. presented new clinical data regarding the immunomodulating activity of plinabulin at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The results demonstrated an 80% disease control rate in non-irradiated tumors among heavily pretreated patients with various cancers. Notably, durable responses were recorded in certain patients with Hodgkin's lymphoma. The data suggests that plinabulin enhances dendritic cell maturation and T-cell proliferation, paving the way for additional studies on its efficacy in immunotherapy-refractory tumors.
Read more →BYSIBeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
BeyondSpring Inc. has presented promising results regarding plinabulin's efficacy in treating glioblastoma, a highly aggressive form of brain cancer, at the 2023 AACR Special Conference. The study showcased plinabulin's ability to effectively kill 3D neurospheres derived from glioblastoma patient cell lines, inhibiting cancer cell survival and invasion. This presentation highlights plinabulin's unique mechanism as a microtubule-targeting agent that can penetrate the blood-brain barrier, pointing to its potential as a novel treatment option in brain cancer therapies.
Read more →BYSIBeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
BeyondSpring Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of October 27, 2023. Following a period where its stock closed above $1.00 per share for 10 consecutive business days, the company has resolved the previously disclosed bid price deficiency. BeyondSpring focuses on developing innovative therapies, including its lead asset Plinabulin, for various cancer indications.
Read more →BYSIBeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
BeyondSpring Inc. announced that they will present a poster at the Society for Immunotherapy of Cancer's 38th Annual Meeting in San Diego, CA. The poster, titled 'Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with Immune Checkpoint Blockade', will be presented by Dr. Steven H. Lin, a notable physician-scientist and radiation oncologist. This event will take place on November 4, 2023, highlighting the company's ongoing efforts in drug discovery and therapy development.
Read more →BYSIBeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
BeyondSpring Inc. announced participation in the R.W. Baird’s 2023 Global Healthcare Conference, taking place in New York City on September 12-13, 2023. This event is a key opportunity for the company to showcase its innovative drug discovery platform. Following the conference, the presentation will be available on their website, facilitating access to the insights shared during the event.
Read more →BYSIBeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
BeyondSpring Inc. announced promising data from a Phase 1 study showcasing Plinabulin's ability to reduce infectious neutropenic fever in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation. Presented at the ASCO Annual Meeting, the study involved 15 patients who received a combination of Plinabulin and pegfilgrastim after high-dose chemotherapy. Notably, the combination showed a favorable safety profile and reduced transfusion needs, suggesting its potential as supportive care for multiple myeloma patients. However, there was no significant reduction in days of severe neutropenia compared to pegfilgrastim alone.
Read more →BYSIBeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
BeyondSpring Inc. announced that it will present a poster at the 2023 ASCO Annual Meeting in collaboration with Memorial Sloan Kettering Cancer Center. The poster will focus on using Plinabulin to improve patient outcomes in those undergoing autologous hematopoietic cell transplant. This event will take place on June 5, 2023, in Chicago, IL, showcasing the innovative research into hematologic malignancies.
Read more →BYSIBeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
BeyondSpring Inc. provided a business update and reported its financial results for the year ending December 31, 2022. The company highlighted the achievements of its subsidiary, SEED Therapeutics, in collaboration with Eli Lilly, which resulted in significant milestone payments. Additionally, enrollment for three investigator-initiated trials featuring the drug candidate Plinabulin has been completed. However, there was a setback as BeyondSpring withdrew its NDA submission for the CIN indication in China, although it plans to re-file shortly.
Read more →BYSIBeyondSpring Files 2022 Annual Report on Form 20-F
BeyondSpring Inc. has filed its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC. The report contains audited consolidated financial statements and highlights the company's ongoing work in drug discovery and development. Key achievements in clinical trials for its lead asset, Plinabulin, are noted, including positive Phase 3 results and meeting primary endpoints in trials. However, the company also acknowledges various risks associated with forward-looking statements.
Read more →BYSIBeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
BeyondSpring has announced the enrollment of the first patient in a Phase 2 trial investigating the combination of Plinabulin, Keytruda, and Docetaxel for treating metastatic non-small cell lung cancer patients who have previously progressed after immunotherapy. The trial is being conducted at Peking Union Medical College Hospital, led by Dr. Mengzhao Wang. This innovative approach aims to provide effective treatment options for patients facing critical survival challenges following immune checkpoint therapy. The study highlights Plinabulin's potential to improve response rates and patient outcomes in a challenging clinical landscape.
Read more →BYSI▲ +9.2%on this news· ran to +31% by day 1
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
BeyondSpring Inc. announced it has regained compliance with the Nasdaq minimum bid price requirement, validating its stock price has been $1.00 or more for ten consecutive business days. However, the company received a notification indicating non-compliance due to not timely filing its Form 6-K for June 30, 2022, and must submit a plan for regaining compliance within 60 days. The firm is actively working on the necessary documentation to maintain its Nasdaq listing.
Read more →BYSI▲ +35.9%on this news· ran to +201% by day 3
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxel In an analysis of breast cancer patients, plinabulin monotherapy was superi
Read more →BYSIBeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet med
Read more →BYSIBeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medi
Read more →BYSI▲ +16.8%on this news
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting
NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medic
Read more →BYSIBeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medic
Read more →BYSI▼ -9.9%on this news· ran to -23% by day 3
BeyondSpring Files 2021 Annual Report on Form 20-F
NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medic
Read more →BYSI▼ -9.9%on this news· ran to -23% by day 3
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
- Company to host call today, April 14, 2022 at 8:00 am ET - Conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or +1-201-389-0879 (International). The passcode is 13728822. The live webcast can be accessed here or by visiting the “investors” section of th
Read more →BYSI▼ -7.1%on this news
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter
Read more →BYSIBeyondSpring Announces Organizational Streamlining - Resources to be Focused on Highest Value Business Activities - 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability
BeyondSpring Announces Organizational Streamlining - Resources to be Focused on Highest Value Business Activities - 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, January 11, 2022 - BeyondSpring Pharmaceuticals (the "Company"
Read more →BYSI▲ +6.4%on this news
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone - IO combination advancement
Read more →BYSI▲ +6.1%on this news
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition
Adding plinabulin to a myelosuppressive chemotherapy regimen rapidly reversed (within 24 hours) chemotherapy-induced neutropenia and leukopenia in the PROTECTIVE-1 and -2 clinical studies, suggesting protection of the granulocyte-monocyte-progenitor stem cells as plinabulin’s mec
Read more →BYSI▼ -7.3%on this newsshared move
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
The two posters will be presented on Friday, December 10, 2021 8:00 AM to 9:30 AM EST NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer t
Read more →BYSI▼ -9.9%on this news
BeyondSpring, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BeyondSpring, Inc. (NASDAQ: BYSI) for potential securities law violations. Investors who have lost money in their BeyondSpring investment should contact the firm to learn more about how they might recover
Read more →BYSI▼ -61.4%on this newsshared move
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced it has received a Complete Response Letter (CRL) from the
Read more →BYSIBeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will participate in a Fireside Chat and host one-on-one in
Read more →BYSIBeyondSpring Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will present at and host one-on-one investor meetings duri
Read more →BYSIBeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors NEW YORK, November 10, 2021 - BeyondSpring Pharmaceuticals (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of innovative cancer t
Read more →BYSIBeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors
—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S. —In the Phase 1 study, plinabulin combination was able to induce tumor responses in patients who had progressed on platinum and checkpoint inhibitors, with 43% ORR
Read more →BYSIBeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC70 of 35 nM The preclinical data is consistent with clinical data in SCLC: pl
Read more →BYSI▼ -33%on this news
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2 nd /3 rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at t
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress
Read more →BYSIBeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of innovative cancer therapeutics, today announced new positive data on plinabulin from its chemo
Read more →BYSIBeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the second quarter ended June 3
Read more →BYSI▲ +5.7%on this newsshared move
BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (
Read more →BYSIBeyondSpring to Participate in the Upcoming September Conferences
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will present at and participate in the Morgan Stanley 19th
Read more →BYSI▼ -12.6%on this newsshared move
BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial result
Read more →BYSI▲ +13.5%on this news
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress
Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as improvement in ORR, PFS, 24- and 36-month OS rates and incidence of Grade 4 neutropenia. NEW YORK, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Be
Read more →BYSI▲ +18.7%on this newsshared move
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China Wanchunbulin, BeyondSpring's 58%-owned subsidiary in China, to partner
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China NEW YORK and SHANGHAI, August 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global
Read more →BYSI▼ -10.9%on this news
BeyondSpring CEO Dr. Lan Huang Named to PharmaVOICE 100 Most Inspiring People in Life Sciences
Distinguished industry executive and entrepreneur recognized for the development of a first-in-class asset in the oncology space NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on
Read more →BYSI▼ -18.4%on this newsshared move
Plinabulin DUBLIN-3 NSCLC Topline Data August 5 2021 | NASDAQ: BYSI Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in respo
Plinabulin DUBLIN-3 NSCLC Topline Data August 5 2021 | NASDAQ: BYSI Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not con
Read more →BYSI▲ +176%on this newsshared move
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2 nd /3 rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Ty
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type NEW YORK, August 4, 2021 (GLOBE NEWSWIRE) -- BeyondSpring
Read more →BYSIBeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney NEW YORK, July 14, 2021 -- BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer th
Read more →BYSIBeyondSpring to Participate in the William Blair Biotech Focus Conference
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech Focus Confere
Read more →BYSIBeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discu
Read more →BYSIBeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update - NDA Filed by U.S. F ood and Drug Administration(FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update - NDA Filed by U.S. Food and Drug Administration(FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned b
Read more →BYSIBeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results
Read more →BYSIBeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had non-inferior protection against CIN compared to pegfilgrastim (day 2 dose), while performing numerica
Read more →BYSIBeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a late-breaking poster presentation of the company’s lead
Read more →BYSIBeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone NEW YORK, June 07, 2021 (GLOBE
Read more →BYSIBeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors
Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination in non-smal
Read more →BYSIBeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021 - Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN prevention for the first time in 30 years NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Be
Read more →BYSIBeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management is scheduled to present at the Jefferies Virtual Healthcare
Read more →BYSIBeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability. - Plinabulin, in combination with nivolumab and ipilimumab, shows 46% objective response rate (ORR) in 13 evaluable patients with PD-1/PD-L1 naïve or resistant t
Read more →BYSIBeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that that CEO Dr. Lan Huang is scheduled to present at the Bank of America S
Read more →BYSIBeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update
- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of CIN - Company subsidiary, SEED Therapeutics, signed an $800 million research
Read more →BYSIBeyondSpring Files 2020 Annual Report on Form 20-F
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the
Read more →BYSIBeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemotherapy-induced neutropenia (CIN) - An additional presentation to focus on plinabuli
Read more →BYSIBeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021
NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter
Read more →BYSIBeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN) - Applications are supported by posit
BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN) NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring"
Read more →BYSIBeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
Webinar on Thursday, March 18th @ 10:00 a.m. ET NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will
Read more →BYSIBEYONDSPRING INC. PROXY STATEMENT General The board of directors of BeyondSpring Inc. (the "Company," "we," "us" or "our") is soliciting proxies for the Extraordinary General Meeting of Shareholders (the "EGM") of the Co
The board of directors of BeyondSpring Inc. (the "Company," "we," "us" or "our") is soliciting proxies for the Extraordinary General Meeting of Shareholders (the "EGM") of the Company to be held on March 15, 2021 at 9 a.m., Eastern Standard Time, at 28 Liberty Street, 39th Floor,
Read more →BYSIBeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the
Read more →BYSIBeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors NEW YORK - December 17, 2020 - BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, to
Read more →BYSIBeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination reduces the odds of having febrile neutropenia by 41% vs. pegfilgrastim alone, based
Read more →BYSIBeyondSpring to Present at Two Upcoming Scientific Conferences in December
BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical compa
Read more →BYSIBeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today
Read more →BYSIBeyondSpring Announces Pricing of Ordinary Shares
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the pricing of its public offering of 7,500,000 ordinary s
Read more →BYSIBeyondSpring Announces Proposed Public Offering of Ordinary Shares
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the launch of an underwritten public offering of $75 milli
Read more →BYSIBeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates - Announced SEED Therapeutics Inc.("SEED")'s collaboration with Eli Lilly and Company("Lilly")
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates - Announced SEED Therapeutics Inc.("SEED")'s collaboration with Eli Lilly and Company("Lilly") NEW YORK, November 17, 2020 - BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: BY
Read more →BYSIBeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia Study met primary endp
BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia NEW YORK, November 16, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the "Company" or "
Read more →BYSIBeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today
Read more →BYSIBeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly - Seed Therapeutics to Use Proprietary "Molecular Glue" Protein Degradation Technology to Develop Potential Ne
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly - Seed Therapeutics to Use Proprietary "Molecular Glue" Protein Degradation Technology to Develop Potential New Medicines - NEW YORK - November 13, 2020 - Seed Therapeu
Read more →BYSIBeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology and chemotherapy-induced neutropenia therapies, announced today that it has
Read more →BYSIBeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer - New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO
BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer - New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO - NEW YORK, N.Y. - September 22, 2020 - Following its recent receipt of two Breakthrough Therapy Designa
Read more →BYSIBeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today
Read more →BYSIBeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) - - Designation Based on PROTECTIVE-
Read more →BYSIBeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates - Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin's Superiority in
BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates - Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin's Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta
Read more →BYSIBeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020
NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 finan
Read more →BYSIBeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors Gilead Acquired Forty Seven in March 2020 for $4.9 Billion
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors Gilead Acquired Forty Seven in March 2020 for $4.9 Billion NEW YORK - August 18, 2020 - BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: B
Read more →BYSIBeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with
Read more →BYSIAmendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan THIS AMENDMENT (this " Amendment ") is made as of
BeyondSpring Inc. 2017 Omnibus Incentive Plan THIS AMENDMENT (this "Amendment") is made as of July 24, 2020, to the BeyondSpring Inc. Omnibus Incentive Plan, as amended from time to time (the "2017 Incentive Plan"). Any capitalized terms used and not defined herein shall have t
Read more →BYSIBeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention -Met P
BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention -Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia P
Read more →BYSIBeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update - PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN - - PROTECTIVE-2 Phase 2 Shows Positive Resul
BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update - PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN - - PROTECTIVE-2 Phase 2 Shows Positive Results in Chemotherapy Optimization with Potentially Better Cl
Read more →BYSIBeyondSpring’s PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes
- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone - - Chemotherapy Dose Reduction and Regimen Downgrade Significantly Impacts Long-term Survival - NEW YORK, June 09, 2020 (GLOBE NEWSWIRE) -- BeyondSprin
Read more →BYSIBeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification
- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin’s Immune Mechanism-Targeted Patient Selection - NEW YORK, June 03, 2020 (G
Read more →BYSIBeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts were accepted a
Read more →BYSIBeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Offi
Read more →BYSIBeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update
- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin for CIN in China in Q1 2020 - - On Track to Report Interim Analysis of Stu
Read more →BYSIBeyondSpring Files 2019 Annual Report on Form 20-F
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the
Read more →BYSIBeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020
NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its fourth-quarter and full-
Read more →BYSIBeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia
- Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years - - Targeting CIN After All Chemotherapies in All Cancer Types in Combination with All G-CSFs - - Strong Patent Protection Through 2036 - NEW YORK, March 30, 2020 (GLO
Read more →BYSIBeyondSpring’s Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy
- New Data to be Presented at NCCN 2020 Annual Conference - NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapi
Read more →BYSIBeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 NEW YORK - March 11, 2020 - BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovativ
Read more →BYSIBeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that new clinical data on the Company’s fi
Read more →BYSIBeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of Drs. Daniel Zabrowski
Read more →BYSIBeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China
Dr. James Tonra Promoted to Chief Scientific Officer Roland Liu Named Chief Commercial Officer for China Subsidiary NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the
Read more →BYSIBeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the peer reviewed journal Cancer Chemotherapy and Pharmacology publishe
Read more →BYSIBeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia ("CIN") in Q1 2020 Plinabulin's Anti-Cancer and CIN Prevention Mecha
BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia ("CIN") in Q1 2020 Plinabulin's Anti-Cancer and CIN Prevention Mechanism Published in Peer Reviewed Journals New York, Decemb
Read more →BYSIBeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will host its third-quarter 2019 financia
Read more →BYSIBeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s abstract for its Phase 3 Study 106 clinical trial design
Read more →BYSIBeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts on the unique mechanism of action for its lead as
Read more →BYSIBeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019
NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s novel trial design for Study 103 with lead asset, Plinabu
Read more →BYSIBeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human R
Read more →BYSIBeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, cli
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors
NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 1
Read more →BYSIBeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today announced that the Company’s novel trial design for DUBLIN-3 (Study BPI-2358-103) for
Read more →BYSIBeyondSpring’s Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that a Company abstract with findings from BeyondSpring’s Study 106 has been accepted for p
Read more →BYSIBeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results - To Submit New Drug Applications ("NDAs") in China for Both Non-Small Cell Lung Cancer ("NSCLC") and Chemotherapy-Induced Neutropenia ("
BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results - To Submit New Drug Applications ("NDAs") in China for Both Non-Small Cell Lung Cancer ("NSCLC") and Chemotherapy-Induced Neutropenia ("CIN") in Q1 2020 - - To Submit NDAs in the United States (
Read more →BYSIBeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019
NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report second-quarter 2019 financia
Read more →BYSIBeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC Presented at 2019 IASLC World Conference on Lung Cancer
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s novel design for Study 103 was selected for poster presentation at the I
Read more →BYSIBeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the
Read more →BYSIBeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstra
Read more →BYSIBeyondSpring Announces Pricing of Public Offering of Ordinary Shares
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the p
Read more →BYSIBeyondSpring Provides Operational Update and First Quarter 2019 Financial Results - New and Compelling Plinabulin Data Presented at Key Scientific Conferences - - To Submit New Drug Applications (NDAs) in China for Both
BeyondSpring Provides Operational Update and First Quarter 2019 Financial Results - New and Compelling Plinabulin Data Presented at Key Scientific Conferences - - To Submit New Drug Applications (NDAs) in China for Both Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy-Induce
Read more →BYSIBeyondSpring Set to Join FTSE Russell 3000 Index
NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join the FTSE Russell 3000® Index at the conclusion of the 2019 Russell indexes annual
Read more →BYSIBeyondSpring to Present at the Jefferies 2019 Healthcare Conference
NEW YORK, June 04, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the Jefferies 2019 Healthcare Conference
Read more →BYSIBeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019
NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s abstract on its lead asset, Plinabulin, has been accepted for poster prese
Read more →BYSIBeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for pub
Read more →BYSIBeyondSpring Files 2018 Annual Report on Form 20-F
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018
Read more →BYSIBeyondSpring Provides Business Update and Fourth Quarter and Full-Year 2018 Financial Results
- Significant Clinical Data Generated for Plinabulin - - On Track to Submit New Drug Applications (NDAs) for Plinabulin to China’s National Medical Products Administration (NMPA) for Both Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy-Induced Neutropenia (CIN) in Q4 2019 -
Read more →BYSIBeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2018 financial results and host an
Read more →BYSIBeyondSpring to Present at the 18th Annual Needham Healthcare Conference
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the 18th Annual Needham Healthcare Conf
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towards Anti-Cancer M1s
NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present a promising new strategy for cancer treatment involving the a
Read more →BYSIBeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient sele
Read more →BYSIBeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will present clinical data on its lead asset, Plinabulin, during a poster
Read more →BYSIBeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, presented new clinical results from its Study 106 program in the prevention of chemotherapy induced neutro
Read more →BYSIBeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin
NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it had a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Ad
Read more →BYSIBeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in
Read more →BYSIBeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention Plinabulin Significantly Reduced Grade 3/4 CIN and Bon
BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention Plinabulin Significantly Reduced Grade 3/4 CIN and Bone Pain When Combined with Neulasta, Compared to Neulasta M
Read more →BYSIBEYONDSPRING PROVIDES OPERATIONAL UPDATE AND SECOND-QUARTER 2018 FINANCIAL RESULTS - Reported Topline Positive Efficacy and Safety Data from Phase 2 Study 106 Evaluating Plinabulin in Combination With Neulasta for Chemot
BEYONDSPRING PROVIDES OPERATIONAL UPDATE AND SECOND-QUARTER 2018 FINANCIAL RESULTS - Reported Topline Positive Efficacy and Safety Data from Phase 2 Study 106 Evaluating Plinabulin in Combination With Neulasta for Chemotherapy-Induced Neutropenia (CIN) - On Track to Report Inte
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment
Data Demonstrating Plinabulin’s Immune-Enhancing Potential Presented at European Society for Medical Oncology (ESMO) Congress NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global, clinical-stage biopharmaceutical company focused on the developme
Read more →BYSIBeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Update Conference Call on October 23, 2018
Dr. Douglas Blayney from Stanford University to Join to Discuss Recently Announced Clinical Data NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therap
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin, Prevents Docetaxel Chemo-Induced-Neutropenia (CIN) Due to a Mechanism of Action Differentiated from G-CSF
Evidence of Neutrophil Demargination and Bone Marrow Transit Time Reduction by Plinabulin Presented at Joint Meeting of the Society for Leukocyte Biology and International Endotoxin and Innate Immunity Society NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ
Read more →BYSIBeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific Conferences
NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present clinical data on its lead asset, Plinabulin, at
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for Neutropenia
Phase 2 Data Show Plinabulin Significantly Reduces Thrombocytopenia in Docetaxel-Treated Patients Compared to Standard of Care Data Presented at 2018 IASLC World Conference on Lung Cancer NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, cl
Read more →BYSIBeyondSpring Strengthens Intellectual Property Portfolio with Newly Granted U.S. Patent for Plinabulin
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the Company a
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
Data Provide Further Support for Plinabulin’s Superior Product Profile Clinical Data Will be Presented at 2018 IASLC 19th World Conference on Lung Cancer NEW YORK , Sept. 06, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical c
Read more →BYSIBeyondSpring to Present at the H.C. Wainwright 20th Annual Global Investment Conference
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Edward Liu, Chief Financial Officer, will present at the H.C. Wain
Read more →BYSIBeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung Cancer
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present clinical data on its lead asset, Plinabulin, du
Read more →BYSIBeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization Daly Brings Significant Commercial and Business Development Experience with Global Pharmaceutical Companies
BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization Daly Brings Significant Commercial and Business Development Experience with Global Pharmaceutical Companies NEW YORK - August 1, 2018 - BeyondSpring Inc. (NASDAQ:BYSI) (
Read more →BYSIBeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today that Dr. Yuankai Shi presented positive data from the Phase 2 portion of
Read more →BYSIBeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results
NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company) (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its financial results for the quarter ended March 31, 2018,
Read more →BYSIBeyondSpring Reports Operational Updates and First Quarter 2018 Financial Results
BeyondSpring Reports Operational Updates and First Quarter 2018 Financial Results NEW YORK, June 21, 2018 - BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer t
Read more →BYSIBeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report first-quarter 2018 financial results on Thur
Read more →BYSIBeyondSpring to Present at Upcoming Conferences
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that management will present at the following conferences in June 2018: B
Read more →BYSIBeyondSpring Announces $20 Million Registered Direct Offering
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring”), a global, clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies, today announced that it has raised aggregate gross proc
Read more →BYSIBeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present results of the Phase 2 portion of Study 105,
Read more →BYSIBeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Lan Huang, Ph.D., Chairman, Chief Executive Officer and Co-Founder of
Read more →BYSIBeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present Phase 2 neutropenia clinical trial data on
Read more →BYSIBeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced the presentation of preclinical data from the Company’s lead asset, Plin
Read more →BYSIBeyondSpring Files Its 2017 Annual Report on Form 20-F
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal yea
Read more →BYSIBeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company”) (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its fourth-quarter and full-year financial results for t
Read more →BYSIBeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial
Read more →BYSIBeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today the appointment of Edward Dongheng Liu as Chief Financial Officer of the
Read more →BYSIBeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company has initiated the Phase 3 portion of Study 105 evaluati
Read more →BYSIBeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies, today announced that Dr. Ramon Mohanlal, the Company’s Chief Medical Office
Read more →BYSIBeyondSpring to Present at Upcoming Investor Conferences
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies, today announced that Dr. Lan Huang, co-founder and CEO, will present at two
Read more →BYSIBeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia
NEW YORK , Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies, today summarized the KOL call with Dr. Douglas Blayney, a long-standing cli
Read more →BYSIBeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member
BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development and commercializati
Read more →BYSIBeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Plinabulin and Neulasta have Very Similar Grade 4 Neutropenia Incidence and Duration of Severe Neutropenia (DSN) in the Phase 2 Portion of Phase 2/3 Trial Study 105 with Docetaxel-Induced Neutropenia Initial Phase 1 Results in Investigator-Initiated Trials Highlight Plinabulin’s
Read more →BYSIBeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company will present initial data from the Phase 2 po
Read more →BYSIBeyondSpring to Present at the 10th Annual Biotech Showcase
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development and commercialization of a pipeline of innovative immuno-oncology cancer therapies, announced
Read more →BYSIBeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has met the primary objective in the Phase 2
Read more →BYSIBeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of innovative immuno-oncology cancer therapies, announced today that the Compan
Read more →BYSIBeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that China has recognized the Company’s lead asset, Plinabulin
Read more →BYSIBeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has initiated its second global Phase 2/3 cli
Read more →BYSIBeyondSpring Reports Third Quarter 2017 Operational and Financial Results New York (N.Y.)
BeyondSpring Reports Third Quarter 2017 Operational and Financial Results New York (N.Y.), November 9, 2017-BeyondSpring Inc. (NASDAQ Capital Markets: BYSI) ("BeyondSpring" or the "Company"), a late-stage clinical biopharmaceutical company focusing on the development of a pipeli
Read more →BYSIBeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment co
Read more →BYSIBeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in China in th
Read more →BYSIBeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline
NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has received two China non-equity diluting gr
Read more →BYSIBeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco
NEW YORK, Oct. 18, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s Chief Medical Officer and Head of Business
Read more →BYSIBeyondSpring to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at the 19th
Read more →BYSIBeyondSpring Provides Operational Update for Second Quarter of 2017 New York (N.Y.)
BeyondSpring Provides Operational Update for Second Quarter of 2017 New York (N.Y.), August 21, 2017-BeyondSpring Inc. (NASDAQ Capital Markets: BYSI) ("BeyondSpring" or the "Company"), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of i
Read more →BYSIBeyondSpring to Present at the 2017 Southern California Investor Conference
NEW YORK , Aug. 17, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ Capital Markets:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that Richard Brand, Chief Financial Officer, will pre
Read more →BYSIBeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment co
Read more →BYSIBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego
NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s Chief Medical Officer and Head of Business Development, Dr.
Read more →BYSIBeyondSpring to Present at the Jefferies 2017 Healthcare Conference
NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at the Jeffe
Read more →BYSIBeyondSpring to Attend Jefferies 2017 Healthcare Conference
NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that senior management, led by Dr. Lan Huang, Ph.D., Chairman and CEO,
Read more →BYSITransformational Science Advancing Oncology Disclaimer This presentation contains forward-looking statements about BeyondSpring Inc. ("BeyondSpring" or the "Company"). Forward looking statements are based on our manageme
Transformational Science Advancing Oncology Disclaimer This presentation contains forward-looking statements about BeyondSpring Inc. ("BeyondSpring" or the "Company"). Forward looking statements are based on our management's beliefs and assumptions and on information currently a
Read more →BYSIBeyondSpring Reports First Quarter 2017 Financial Results New York (N.Y.), May [22], 2017-BeyondSpring Inc. (NASDAQ Capital Markets: BYSI) ("BeyondSpring" or the "Company"), a late-stage clinical biopharmaceutical compan
BeyondSpring Reports First Quarter 2017 Financial Results New York (N.Y.), May [22], 2017-BeyondSpring Inc. (NASDAQ Capital Markets: BYSI) ("BeyondSpring" or the "Company"), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of innovative i
Read more →BYSIBeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017
NEW YORK, May 08, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s Chief Medical Officer and Head of Business Development, Dr.
Read more →BYSITransformational Science Advancing Oncology
Transformational Science Advancing Oncology Disclaimer This presentation contains forward - looking statements about BeyondSpring Inc. ("BeyondSpring" or the "Company"). Forward looking statements are based on our management's beliefs and assumptions and on information currently
Read more →BYSIBeyondSpring Files Its 2016 Annual Report on Form 20-F
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal year
Read more →BYSIBeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results
NEW YORK, April 28, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ Capital Markets:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, today provided an operational update to the investment community, inc
Read more →BYSIBeyondSpring to Participate in Joseph Gunnar’s Pioneers 2017 Conference on May 2 in New York
NEW YORK, April 26, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at Joseph Gunnar's
Read more →BYSIBeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention
NEW YORK, April 25, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company has enrolled the first patient at the Hematology / Oncology
Read more →BYSIBeyondSpring to Host Quarterly Operational Update Conference Call on April 28, 2017
NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment c
Read more →BYSIBeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017
NEW YORK, March 22, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s Chief Medical Officer and Head of Business Development, Ra
Read more →BYSIBeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that an abstract on the molecular action describing the immunological involve
Read more →BYSIBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s clinical trial data for its innovative lead asset, Plinabu
Read more →BYSIBeyondSpring Inc. Prices Initial Public Offering and Concurrent Private Placement of $54.31 M
NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”), a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced the pricing of its initial public offering of 174,286 ordinary shares at a public
Read more →BYSIBeyondSpring Inc. (Nasdaq: BYSI) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, March 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (Nasdaq:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, will visit the Nasdaq MarketSite in Times Square, in celebration of its init
Read more →BYSIBeyondSpring Pharmaceuticals to Present Today at 4th Annual Cancer Biopartnering & Investment Forum in NYC
NEW YORK, Feb. 24, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound and a strong pipeline in collaboration with Fred Hutc
Read more →BYSIBeyondSpring Pharmaceuticals’ Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC
NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound and a strong pipeline in collaboration with Fred Hutc
Read more →BYSIBeyondSpring Pharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference
NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound and a strong pipeline in collaboration with Fred Hutc
Read more →BYSIBeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase
NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound, Plinabulin, today announced that Dr. Lan Huang, co-f
Read more →BYSIBeyondSpring Pharmaceuticals and Fred Hutchinson Cancer Research Center Enter Collaboration Agreement
NEW YORK, Jan. 06, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound Plinabulin, today announced that they have entered in
Read more →BYSIBeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR’s 2016 Tumor Microenvironment Special Conference
NEW YORK, Jan. 05, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound, today announced that data related to an immune-media
Read more →BYSIBeyondSpring Pharmaceuticals Granted CTA by CFDA to Initiate China Arm of Global Phase III Trial of Lead Asset Plinabulin
NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the China Food and Drug Administration (“CFDA”) has given a CT
Read more →BYSIBeyondSpring Data Demonstrating Activity of Plinabulin in Kras-Mutant Tumors Presented at AACR-NCI-EORTC International Conference 2015
NEW YORK, Nov. 17, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced data from a series of preclinical studies demonstrating that its lead compound Pli
Read more →BYSIBeyondSpring Announces Appointments of Dr. Ramon Mohanlal as Chief Medical Officer and Robert Dickey IV as Chief Financial Officer
NEW YORK, Oct. 30, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointments of Ramon Mohanlal, M.D., Ph.D. as its Chief Medical Officer and R
Read more →BYSIBeyondSpring Announces Positive Follow-Up Results for Phase 2 Trial of Plinabulin in Advanced NSCLC at WCLC 2015
NEW YORK, Sept. 15, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that data supporting the ongoing development of its lead compound, Plinabulin, we
Read more →BYSIBeyondSpring Announces Planned Start of Phase I Investigator-Initiated Trial of Plinabulin Plus Nivolumab, Enters Immuno-Oncology Space
NEW YORK, Sept. 15, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that a Phase I investigator-initiated trial is planned to start, with first patie
Read more →BYSIBeyondSpring to Present Two Posters Supporting Plinabulin at WCLC 2015
NEW YORK, Aug. 31, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that its lead compound, Plinabulin, will be presented in two posters at the upcomi
Read more →BYSIBeyondSpring Extends Plinabulin IP Portfolio With Two New Method of Treatment Patent Applications
NEW YORK, March 23, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United
Read more →BYSIBeyondSpring Files Composition of Matter Patent Application for Plinabulin Combination Therapy in Immuno-Oncology
NEW YORK, Feb. 24, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed a composition of matter patent application with the United State
Read more →BYSIBeyondSpring Pharmaceuticals Names Dr. Yan Sun as Principal Investigator for Global Phase 3 Lung Cancer Clinical Trial of Plinabulin
NEW YORK, Dec. 9, 2014 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that leading thoracic oncologist in China Dr. Yan Sun has been named the principal invest
Read more →BYSIBeyondSpring Pharmaceuticals to Conduct Phase 3 Trial of Lead Candidate Plinabulin in NSCLC
NEW YORK, Dec. 3, 2014 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinab
Read more →Competitive Position
How BYSI ranks across every disease it competes inCompetitive Position is a premium feature
See how BYSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial